Chris Schott
Stock Analyst at JP Morgan
(3.68)
# 878
Out of 4,413 analysts
58
Total ratings
57.58%
Success rate
3.81%
Average return
Main Sectors:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $270 → $240 | $214.82 | +11.72% | 2 | Apr 11, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $775 → $850 | $781.10 | +8.82% | 10 | Mar 15, 2024 | |
| TEVA Teva Pharmaceutical | Upgrades: Neutral | $14 | $14.05 | -0.36% | 4 | Mar 8, 2024 | |
| PRGO Perrigo Company | Maintains: Overweight | $48 → $41 | $32.66 | +25.54% | 4 | Feb 28, 2024 | |
| RPRX Royalty Pharma | Maintains: Overweight | $45 → $42 | $27.70 | +51.62% | 4 | Feb 20, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $600 → $630 | $492.76 | +27.85% | 5 | Feb 6, 2024 | |
| AMGN Amgen | Reinstates: Neutral | $270 | $273.94 | -1.44% | 1 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $36 → $34 | $25.62 | +32.71% | 3 | Oct 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $900 → $950 | $890.66 | +6.66% | 2 | Mar 31, 2023 | |
| MRK Merck & Co. | Maintains: Overweight | $120 → $125 | $129.22 | -3.27% | 4 | Feb 23, 2023 | |
| VTRS Viatris | Maintains: Neutral | $13 → $14 | $11.57 | +21.00% | 2 | Nov 15, 2022 | |
| CHRS Coherus BioSciences | Maintains: Neutral | $13 → $11 | $1.96 | +461.22% | 2 | Nov 14, 2022 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $24 → $20 | $13.16 | +51.98% | 3 | Oct 17, 2022 | |
| ZTS Zoetis | Maintains: Overweight | $250 → $225 | $159.24 | +41.30% | 1 | Oct 17, 2022 | |
| GILD Gilead Sciences | Upgrades: Overweight | $72 → $80 | $65.20 | +22.70% | 1 | Oct 4, 2022 | |
| BHC Bausch Health Companies | Downgrades: Neutral | n/a | $8.76 | - | 3 | Jul 29, 2022 | |
| OGN Organon & Co. | Initiates: Neutral | n/a | $18.61 | - | 1 | Jun 15, 2021 | |
| TXMD TherapeuticsMD | Downgrades: Neutral | n/a | $1.88 | - | 1 | May 19, 2020 | |
| KALA Kala Pharmaceuticals | Maintains: Overweight | n/a | $6.82 | - | 2 | Nov 14, 2018 | |
| PCRX Pacira BioSciences | Maintains: Neutral | n/a | $26.25 | - | 2 | Nov 2, 2018 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | n/a | $43.94 | - | 1 | Oct 8, 2018 |
Biogen
Apr 11, 2024
Maintains: Neutral
Price Target: $270 → $240
Current: $214.82
Upside: +11.72%
Eli Lilly
Mar 15, 2024
Maintains: Overweight
Price Target: $775 → $850
Current: $781.10
Upside: +8.82%
Teva Pharmaceutical
Mar 8, 2024
Upgrades: Neutral
Price Target: $14
Current: $14.05
Upside: -0.36%
Perrigo Company
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $32.66
Upside: +25.54%
Royalty Pharma
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $27.70
Upside: +51.62%
IDEXX Laboratories
Feb 6, 2024
Maintains: Overweight
Price Target: $600 → $630
Current: $492.76
Upside: +27.85%
Amgen
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $273.94
Upside: -1.44%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.62
Upside: +32.71%
Regeneron Pharmaceuticals
Mar 31, 2023
Maintains: Overweight
Price Target: $900 → $950
Current: $890.66
Upside: +6.66%
Merck & Co.
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $129.22
Upside: -3.27%
Viatris
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $11.57
Upside: +21.00%
Coherus BioSciences
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.96
Upside: +461.22%
Elanco Animal Health
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $13.16
Upside: +51.98%
Zoetis
Oct 17, 2022
Maintains: Overweight
Price Target: $250 → $225
Current: $159.24
Upside: +41.30%
Gilead Sciences
Oct 4, 2022
Upgrades: Overweight
Price Target: $72 → $80
Current: $65.20
Upside: +22.70%
Bausch Health Companies
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.76
Upside: -
Organon & Co.
Jun 15, 2021
Initiates: Neutral
Price Target: n/a
Current: $18.61
Upside: -
TherapeuticsMD
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.88
Upside: -
Kala Pharmaceuticals
Nov 14, 2018
Maintains: Overweight
Price Target: n/a
Current: $6.82
Upside: -
Pacira BioSciences
Nov 2, 2018
Maintains: Neutral
Price Target: n/a
Current: $26.25
Upside: -
Bristol-Myers Squibb Company
Oct 8, 2018
Maintains: Overweight
Price Target: n/a
Current: $43.94
Upside: -